Assistant Professor of Medicine, Ohio State University
Hematology
Dr. Spero R. Cataland, MD
|
|
Give Review
Spero Cataland works in the field of Hematology. He attended The Ohio State University College of Medicine. He received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Spero Cataland is also a published physician. He has 50 paper published. The most recent paper is: The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Spero Cataland is registered with Medicare and accepts Medicare payments.
Publications
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
- Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers.
- Clinical utility of complement biomarkers in the diagnosis and treatment of Acute thrombotic microangiopathies.
- Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients With acquired thrombotic thrombocytopenic purpura.
- Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP.
- How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic Syndrome.
- Eculizumab Therapy.
- Diagnosis and management of complement mediated thrombotic microangiopathies.
- Atypical hemolytic uremic Syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies.
- Complement Activation and Mortality During an Acute Episode of Thrombotic Thrombocytopenic Purpura.
- Relapse of aHUS after discontinuation of therapy With eculizumab in a patient With aHUS and factor H mutation.
- Profound neurological injury in a patient with atypical hemolytic uremic Syndrome.
- Practical Issues in ADAMTS13 Testing and Emerging Therapies in Thrombotic Thrombocytopenic Purpura.
- 3 Rs: rituximab, remission, relapse.
- Myeloid growth factors.
- Venous thromboembolic disease.
- ADAMTS13 activity and antigen during therapy and follow-up of patients With idiopathic thrombotic thrombocytopenic purpura: correlation With clinical outcome.
- ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in Pregnancy.
- Evidence of persistent neurologic injury following thrombotic Thrombocytopenic purpura.
- Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic Syndrome.
- TTP disease course is independent of Myeloma treatment and response.
- Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients With idiopathic thrombotic thrombocytopenic purpura.
- Rapid determination of ADAMTS13 activity improves clinical decision-making.
- Immunotherapy for thrombotic Thrombocytopenic purpura.
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed Acute leukemia.
- Leukocytoreduction for Acute leukemia.
- Validation of claims-based diagnostic codes for idiopathic thrombotic Thrombocytopenic purpura in a commercially-insured population.
- Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients With acquired idiopathic thrombotic thrombocytopenic purpura.
- Myeloid growth factors clinical practice guidelines in oncology.
- Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.
- Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
- Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic Thrombocytopenic purpura.
- Long-term, sub-clinical cardiac and renal complications in patients With multiple relapses of thrombotic thrombocytopenic purpura.
- Myocardial ischemia and right ventricular dysfunction in adult patients with sickle Cell disease.
- Venous thromboembolic disease. Clinical practice guidelines in oncology.
- An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic Thrombocytopenic purpura.
- Targeting the inhibitor of ADAMTS13 in thrombotic Thrombocytopenic purpura.
- Myeloid growth factors. Clinical practice guidelines in oncology.
- Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up With serial analysis of ADAMTS13 activity.
- Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.
- A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and Acute myeloid leukemia.
- A rapid test for the diagnosis of thrombotic Thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.
- An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic Thrombocytopenic purpura.
- Full evaluation of an acquired case of thrombotic Thrombocytopenic purpura following the surgical resection of glioblastoma multiforme.
- Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients With insulin-dependent (type 1)...
- The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients With noninsulin-dependent diabetes.
- Preliminary experience with a new chemotherapy regimen for adults with Acute lymphoblastic leukemia.
- Antibody therapy of Acute and chronic leukemias.
- Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome.
Schools
Ohio State University College Of Medicine and Public Health
Oh State University Hospital
University Of Chicago Hosps
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
Ohio State University Hospital -
The Ohio State University College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1881602209 | |
| NPPES Provider LastName | CATALAND | |
| NPPES Provider FirstName | SPERO | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 691.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 192.0 | |
| Percent Opioid Claims | 27.79 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881602209 |
| Last Name Of The Provider | CATALAND |
| First Name Of The Provider | SPERO |
| View All |
Similar Doctors
|
Dr. Mark S. Collins, MD |
|
Dr. Beth A. Christian, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Arvinder S. Bhinder, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Yvonne A. Efebera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott C. Blair, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kami J. Maddocks-Christianson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nseobong I. Ntukidem, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert A. Baiocchi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Alison R. Walker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy D. Moore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerry T. Guy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard B. Zellmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lapo Alinari, MD |